Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.800
-0.130 (-2.64%)
Jun 12, 2025, 9:54 AM - Market open
Y-mAbs Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Revenue | 88.66 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 | Upgrade
|
| Revenue Growth (YoY) | 4.92% | 3.38% | 29.96% | 87.03% | 68.18% | - | Upgrade
|
| Cost of Revenue | 16.11 | 15.25 | 11.42 | 7.57 | 2.51 | 2.2 | Upgrade
|
| Gross Profit | 72.55 | 72.43 | 73.4 | 57.7 | 32.38 | 18.55 | Upgrade
|
| Selling, General & Admin | 51.27 | 50.13 | 44.5 | 52.47 | 56.94 | 45.9 | Upgrade
|
| Research & Development | 45.1 | 47.41 | 50.09 | 88.55 | 90.88 | 92.58 | Upgrade
|
| Operating Expenses | 96.37 | 97.54 | 94.59 | 141.02 | 147.82 | 138.48 | Upgrade
|
| Operating Income | -23.82 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 | Upgrade
|
| Interest Expense | - | - | - | - | -1.85 | - | Upgrade
|
| Interest & Investment Income | 4.34 | 3.43 | 4.28 | 0.64 | - | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.04 | -2.04 | 0.52 | - | - | 0.58 | Upgrade
|
| EBT Excluding Unusual Items | -21.52 | -23.72 | -16.38 | -82.68 | -117.29 | -119.34 | Upgrade
|
| Merger & Restructuring Charges | -2.45 | -1.52 | -4.48 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 62.01 | - | Upgrade
|
| Asset Writedown | - | - | - | -0.62 | - | - | Upgrade
|
| Legal Settlements | -3.85 | -3.85 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.72 | -0.72 | - | -12.28 | - | - | Upgrade
|
| Pretax Income | -28.53 | -29.81 | -20.87 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Income Tax Expense | -0.3 | -0.15 | 0.56 | - | - | - | Upgrade
|
| Net Income | -28.23 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Net Income to Common | -28.23 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 44 | 44 | 44 | 43 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 44 | 44 | 44 | 43 | 40 | Upgrade
|
| Shares Change (YoY) | 2.26% | 1.57% | -0.13% | 1.21% | 7.64% | 14.03% | Upgrade
|
| EPS (Basic) | -0.63 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 | Upgrade
|
| EPS (Diluted) | -0.63 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 | Upgrade
|
| Free Cash Flow | -19.28 | -15.71 | -27.23 | -75.92 | -103.22 | -91.41 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.35 | -0.62 | -1.74 | -2.39 | -2.28 | Upgrade
|
| Gross Margin | 81.84% | 82.61% | 86.54% | 88.41% | 92.80% | 89.38% | Upgrade
|
| Operating Margin | -26.87% | -28.64% | -24.98% | -127.66% | -330.78% | -578.00% | Upgrade
|
| Profit Margin | -31.85% | -33.83% | -25.26% | -146.43% | -158.40% | -575.12% | Upgrade
|
| Free Cash Flow Margin | -21.74% | -17.92% | -32.11% | -116.32% | -295.79% | -440.51% | Upgrade
|
| EBITDA | -23.37 | -24.58 | -20.46 | -82.48 | -114.65 | -119.54 | Upgrade
|
| EBITDA Margin | -26.36% | -28.03% | -24.12% | -126.37% | - | - | Upgrade
|
| D&A For EBITDA | 0.45 | 0.54 | 0.74 | 0.84 | 0.78 | 0.4 | Upgrade
|
| EBIT | -23.82 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 | Upgrade
|
| EBIT Margin | -26.87% | -28.64% | -24.98% | -127.66% | - | - | Upgrade
|
| Revenue as Reported | 88.66 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.